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To investigate the roles and mechanisms of miR-33a in liver fibrosis, miR-33a expression in whole liver and 
serum samples was measured from chronic hepatitis B (CHB) patients by quantitative real-time PCR 
(qRT-PCR). In addition, Human and murine primary liver fibrosis-associated cells were isolated and treated 
with transforming growth factor-β1 (TGF-β1). We found that miR-33a expression levels in liver tissue 
significantly increased with a fibrosis progression manner in the human liver. Furthermore, serum miR-33a 
levels associated positively with progressing process of hepatic fibrosis. miR-33a was in particular increased in 
hepatic stellate cells (HSC) than other liver fibrosis-associated cells. Stimulation of HSCs with TGF-β1 leads to a 
critical increase of miR- 33a. Increasing miR-33a levels increased (whereas inhibiting miR-33a weakened) the 
activation role of TGF-β1 in LX-2 cells, which might be a potential mechanism through moderating Smad7 
expression. Altogether, data suggest that miR-33a may be a novel marker for HSC activation and hepatic 
fibrosis progress, suggesting a new therapeutic target in liver fibrosis. 
To cite this article: Chuan-Feng Huang, et al. miR-33a, an important marker and putative therapeutic target in chronic 
HBV-induced fibrosis. RNA Dis 2014; 1: e416. doi: 10.14800/rd.416. 
Liver fibrosis is the late stage of different chronic liver 
diseases, and in China, chronic hepatitis B virus (HBV) 
infection has been identified as the main cause of liver 
fibrosis. Fibrosis is characterized by excessive production 
and deposition of extracellular matrix (ECM) proteins, 
mainly the type I collagen that is synthesized by hepatic 
stellate cells (HSCs) after various fibrogenic stimulation 
[1, 2]
.
Growing evidence has demonstrated that transforming 
growth factor-β1 (TGF-β1) plays a central role in liver 
fibrosis 
[3, 4]
. However, despite advanced knowledge in
understanding the pathophysiology of hepatic fibrosis, the 
underlying mechanisms of this process remain unclear.  
A microRNA (miRNA) is a small newly discovered 
endogenous non-coding RNA molecule that contains 18–25 
nucleotides and perform as post-transcriptional regulators of 





. microRNA-33a (miR-33a) recently has become
a hot research small miRNA and it has been demonstrated 
that it not only regulates lipid homeostasis 
[8–11]
, but also may
be exerting as a potent tumor suppressor 
[12]
, cell
proliferation and cycling 
[13]
. Moreover, Li et al. 
[14]
 recently
demonstrated that miR-33a-associated HSC activation and 
extracellular matrix production was, at least in part, 
modulated by the activation of the PI3K/Akt pathway and 
PPAR-α in vitro, and they found that the expression of 
miR-33a was associated with the progression of liver 
fibrosis. However, the role and mechanism of miR-33a on 
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hepatic fibrosis is largely unknown.  
In this work we investigated the profibrogenic effects and 
associated mechanisms of miR-33a in hepatic fibrosis. Our 
results showed that serum and hepatic miR-33a levels 
increased with the progression of liver fibrosis in CHB 
patients and expression of miR-33a was significantly 
upregulated in primary hepatocytes and hepatic stellate cells 
from C57BL/6 murine hepatic fibrosis models as previously 
described 
[15-17]
. Moreover, miR-33a expression in HSCs is 
higher than another fibrosis-associated cell hepatocytes (e.g., 
LX-2, HepG2 and Huh7 cells), both of which were isolated 
from human and mice liver. Interestingly, the expression 
pattern of miR-33a in the human or mice hepatocyte was not 
altered after TGF-β1 treatment. These results confirm that 
miR-33a expression was specifically expressed in the 
activation process of hepatic stellate cells, and suggest that 
miR-33a is regulated in whole liver extracts in mice and 
human hepatic fibrosis, which was not dependent on the type 
of experimental model of liver fibrosis. 
A growing amount of evidence has demonstrated that 
TGF-β1 and its activation role of HSCs plays a central role in 
the progression of hepatic fibrosis 
[18]
. Our results shown that 
TGF-β1 modulates miR-33a expression in a dose- and 
time-dependent manner in HSCs, increasing miR-33a levels 
increased (whereas inhibition miR-33a decreased) 
TGF-β1-induced collagen I (Col1A1) and alpha-smooth 
muscle actin (a-SMA) protein levels in HSCs, mRNA 
expression of Col1A1 and a-SMA was exerted in a manner 
similar to miR-33a expression. These results indicate that the 
profibrotic effects of miR-33a might be modulated by 
modulation of TGF-β1-associated signaling pathway. 
TGF-β1 predominantly activates hepatic stellate cells (HSC) 
via the TGF-β1/Smad signaling pathway, thus resulting in 
liver fibrosis 
[19, 20]
. Our results first showed that 
TGF-β1-induceded miR-33a expression and miR-33a 
alternately stimulated TGF-β1- induced HSC fibrogenic 
activation by targeting the inhibitory Smad, Smad7. 
However, Smad7 inhibition might not be the only 
mechanisms about miR-33a profibrogenic effects. Thus, it 
needs further investigation in the future.  
According to our results, we assume that miR-33a is, at 
least in part, a novel signaling pathway that modulates 
TGF-β1-dependent induction of ECM genes (e.g., ColA1, 
a-SMA) in hepatic stellate cells during liver fibrosis. To our 
knowledge, this study is the first clinical investigation to 
identify miR-33a is a hepatic fibrogenesis associated 
microRNA molecules. Overall, our findings imply that 
miR-33a plays a central role in the pathogenesis of hepatic 
fibrosis and is a new marker for clinical diagnosis, which 
may be developed as a potential therapeutic target in treating 
liver fibrosis. However, in the current study, the scale of this 
study was too small, a large sample size is needed for future 
investigations.  
In summary, we found that miR-33a might be a new 
marker for hepatic stellate cell activation and hepatic 
fibrogenesis processes in both humans and mice. MiR-33a 
could be used to exploit future diagnostic and therapeutic 
tools to treat liver fibrosis. 
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